At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 92 enrolled
Drug / intervention
Phenazopyridine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Oral phenazopyrIdine on Perioperative Voiding After Mid-urethral Sling
In Brief
A Phase 3 clinical trial evaluating Phenazopyridine and no Phenazopyridine for Dysfunctional Voiding and Postoperative Pain. Completed, enrolled 92 participants across 1 site.
Detailed Summary
Randomized clinical trial using phenazopyridine to decrease voiding dysfunction after a retropubic midurethral sling operation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysfunctional Voiding, Postoperative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedJun 2016
Primary CompletionAug 2017
TodayJul 2026
First PostedJun 21, 2016
Enrollment StartFeb 1, 2016
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.0 years ago
Interventions
Phenazopyridinedrug
no Phenazopyridineother
Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided